

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the “Announcement in Relation to the Acceptance of a Subsidiary’s Drug Registration Application” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

6 June 2024

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *for identification purposes only*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to the Acceptance of a Subsidiary's Drug Registration Application

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, the drug registration application for Luvometinib Tablets (project code: FCN-159 tablets, the “**Investigational New Drug**”) independently developed by Shanghai Fosun Pharmaceutical Industrial Development Company Limited* (上海復星醫藥產業發展有限公司), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司) (the “**Company**” and, together with its subsidiaries/units, the “**Group**”, the same applies below) for the treatment of NF1(type 1 neurofibroma)-associated plexiform neurofibromas in children aged 2 years and over, has been accepted by the National Medical Products Administration (“NMPA”) and included in the List of Priority Review.

II. Basic Information and Research Progress of the Investigational New Drug

The Investigational New Drug is an innovative small molecule chemical drug self-developed by the Group, which is a MEK1/2 selective inhibitor and is intended to be used primarily for the treatment of advanced solid tumors, type 1 neurofibromas, dendritic cell and histiocytic neoplasms and low-grade glioma.

As of April 2024, the cumulative research and development investment of the Group in the Investigational New Drug at this stage amounted to RMB499.15 million (unaudited).

As at the date of this announcement, the drug registration application of the Investigational New Drug for the treatment of adult dendritic cell and histiocytic neoplasms, has been accepted by the NMPA and included in the List of Priority Review. The Investigational New Drug is at the stage of Phase III clinical trial in China (excluding Hong Kong, Macao and Taiwan region for the purpose of this announcement, the same applies below) for the treatment of type 1 neurofibroma in adults, and the Investigational New Drug is at the stage of Phase II clinical trial in China for the treatment of low-grade glioma, arteriovenous malformations, childhood Langerhans cell histiocytosis, respectively. The Investigational New Drug has been granted breakthrough therapy designation by the Center for Drug Evaluation of the NMPA for the treatment of two indications of histiocytic neoplasms and type 1 neurofibroma in adults.

As at the date of this announcement, the MEK1/2 selective inhibitor approved for launch worldwide includes Trametinib of Novartis, Binimetinib of Array Biopharma, Selumetinib of AstraZeneca and Cobimetinib of Roche, etc. According to the latest data from IQVIA MIDAS^{TM1}, the sales of MEK1/2 selective inhibitor worldwide amounted to approximately US\$1,810 million in 2023.

III. Risk Reminder

The Investigational New Drug is subject to, among others, the passing of the GMP compliance inspection and the drug registration approval before commercial production. This acceptance of the drug registration application review will not have a material impact on the results of the Group at this stage.

Due to the industry characteristics of pharmaceutical products, the specific sales performance after the market launch of pharmaceutical products may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, etc., and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

Board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

6 June 2024

*For identification purpose only

¹ Data provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world.